A response to someone on Yahoo message board. I
Post# of 154725
(Total Views: 806)
Posted On: 07/20/2021 8:25:19 AM
A response to someone on Yahoo message board.
In response to Bruce. My, my people will try to discredit at all costs.
1. CTCs and CAMLs have been a hallmark of testing in both trials since the beginning. The 72% suggests 29 patients with 1 dropout for unknown reasons.
2. Multiply .72 by 300% and 450% and you'll get reasonably close to the overall trial responses. In phase 3 trials there will almost certainly be exclusions that would bring the numbers into line with the 300% and 450%. Actually those numbers should increase with exclusions and optimal dosing.
3. The 72% would be in line with 22 having reduction in CAMLS and 7 not. 29 total patients.
4. Trodelvy the last approved drug for mTNBC had a median overall survival rate of 10.9 months. At 12 months leronlimab had such a high survival rate that median overall survival could only be classified as 12+ months.
5. Not knowing what comparison they used the percentages are fairly meaningless. Refer to the superior numbers mPFS and the mOS.
6. Without knowing what the comparators are the percentages are fairly meaningless mPFS and mOS are not.
7. Most likely is 29 patients. We know their were 9 in the clinical trial and so 20 must be from compassionate use. Which gives us 23 patients that were on the less effectual 350mg dose for at least some of that time and possibly 20 for the full trial if compassionate use protocol was followed. Which would make 700mg results even more astounding.
In response to Bruce. My, my people will try to discredit at all costs.
1. CTCs and CAMLs have been a hallmark of testing in both trials since the beginning. The 72% suggests 29 patients with 1 dropout for unknown reasons.
2. Multiply .72 by 300% and 450% and you'll get reasonably close to the overall trial responses. In phase 3 trials there will almost certainly be exclusions that would bring the numbers into line with the 300% and 450%. Actually those numbers should increase with exclusions and optimal dosing.
3. The 72% would be in line with 22 having reduction in CAMLS and 7 not. 29 total patients.
4. Trodelvy the last approved drug for mTNBC had a median overall survival rate of 10.9 months. At 12 months leronlimab had such a high survival rate that median overall survival could only be classified as 12+ months.
5. Not knowing what comparison they used the percentages are fairly meaningless. Refer to the superior numbers mPFS and the mOS.
6. Without knowing what the comparators are the percentages are fairly meaningless mPFS and mOS are not.
7. Most likely is 29 patients. We know their were 9 in the clinical trial and so 20 must be from compassionate use. Which gives us 23 patients that were on the less effectual 350mg dose for at least some of that time and possibly 20 for the full trial if compassionate use protocol was followed. Which would make 700mg results even more astounding.
(34)
(1)